8
Participants
Start Date
August 31, 2014
Primary Completion Date
June 30, 2018
Study Completion Date
June 30, 2018
SB-728mR-T
-SB-728mR-T infusions of 2 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
SB-728mR-T
\- SB-728mR-T infusions of 3 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
Cyclophosphamide
\- IV cyclophosphamide 1 g/m2 two days prior to the first SB-728mR-T infusion
Orlando
Dallas
Austin
San Francisco
Norwalk
Lead Sponsor
Sangamo Therapeutics
INDUSTRY